Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2006

View Archived Issues

Tanabe Seiyaku presents clinical highlights of past year

Nilotinib highlights from ASCO 2006

Recent data from lapatinib clinical trials presented

MBP-8298 delays multiple sclerosis progression in HLA class II subgroup

Analysis correlates efaproxiral concentrations with clinical benefit

Takara Bio to jointly develop AIDS gene therapy with China institute

Pivotal study of rhThrombin completes enrollment

IMPACT studies of OvaRex complete enrollment

Trials further reveal indiplon efficacy and safety in patients with insomnia

Effects of CX-717 on EEG spectra assessed after sleep deprivation

Novel histamine H1 agonist as a clinical candidate for sleep maintenance insomnia

VEC-162: rapidly shifts circadian phases to improve sleep properties

Roche and Evotec partner in CNS drug discovery and development

T-5224 enters phase I in Japan for rheumatoid arthritis

rEV-131 studied in new trial for inflammation following cataract surgery

SkyePharma reviews pipeline development

Schering AG acquires Celera Genomics' cathepsin S inhibitor program

Lundbeck to advance Lu-AA21004 for depression

CTCE-0214 to be studied for repopulating blood stem cell

Athenagen to begin phase I/II study of wound healing agent ATG-002

AEterna Zentaris to advance cetrorelix into phase III for BPH

NDA submission for Cyanokit for cyanide poisoning

Orphan drug designation for MORAb-003 in ovarian cancer

EMEA recommends orphan drug designation for GV-1001 in pancreatic cancer

European approval of Acomplia

Arginase: a novel target for diabetes

Inhibition of hepatic micro RNA regulates lipid metabolism in vivo

Novel treatment options for metabolic disorders described in recent patents

Novel agents for cardiovascular disorders disclosed

Recent patents describe therapeutic agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...